Streetbeat News

VNRX

VolitionRx Limited

https://www.volition.com

Industry

Medical - Diagnostics & Research

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

Open

0.61

Mkt cap

61M

Volume

269K

High

0.69

P/E Ratio

-1.64

52-wk high

1.23

Low

0.58

Div yield

N/A

52-wk low

0.43

EF Hutton analyst Tim Moore has maintained a Buy rating on VolitionRX (AMEX:VNRX) with a price target of $4.5.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 5:11 pm

VolitionRX reported Q1 2024 earnings with a GAAP EPS of $(0.10), beating estimates by 9.09% but missed sales estimates by 55.96%, reporting $171.535K against an expected $389.500K.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 8:57 pm

In Tuesday's intraday session, several healthcare stocks experienced significant movements. VolitionRX, Palisade Bio, Kintara Therapeutics, Protagenic Therapeutics, BIMI Intl Medical, and NKGen Biotech were among the gainers, with increases ranging from 20.4% to 33.6%. Conversely, Abeona Therapeutics, Rezolute, Jaguar Health, Adlai Nortye, Sunshine Biopharma, and Portage Biotech saw declines between 12.49% and 52.3%.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 4:31 pm

In Tuesday's pre-market session, several healthcare stocks showed significant movement. ImmunityBio (IBRX) led the gainers with a 32.0% increase, while Abeona Therapeutics (ABEO) experienced the largest drop among the losers, declining by 45.7%. Other notable movers included Nuwellis (NUWE), VolitionRX (VNRX), and Tiziana Life Sciences (TLSA) with substantial gains, and OncoCyte (OCX), T2 Biosystems (TTOO), and Jaguar Health (JAGX) with notable losses.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 12:06 pm

VolitionRx shares surged following the announcement of the availability of its Nu.Q Vet Cancer Test in the US and Europe, marking a significant milestone for the company.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 12:04 pm

VolitionRx has announced that its Nu.Q Vet Cancer Test is now available for in-clinic use across the US and Europe through a partnership with Antech. This expansion could significantly impact VolitionRx's market presence and revenue streams, as it makes its innovative cancer detection technology more accessible to veterinarians and pet owners.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 12:03 pm

Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating on VolitionRX (AMEX:VNRX) and maintained a $2.5 price target.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 1:55 pm

EF Hutton analyst Tim Moore has reaffirmed a Buy rating on VolitionRX (AMEX:VNRX) with a maintained price target of $4.5.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 1:43 pm

VolitionRX (AMEX:VNRX) reported Q4 earnings with EPS of $(0.11), meeting analyst estimates, but missed sales forecasts with $243.97K versus the expected $450.00K. Despite the sales miss, this represents a significant increase over the previous year's figures.

Portfolio Pulse from Happy Mohamed

March 25, 2024 | 8:28 pm

VolitionRx Limited (VNRX) reported a significant increase in cash and cash equivalents, totaling approximately $20.7 million as of December 31, 2023, compared to $10.9 million the previous year. The company also saw a 153% increase in revenue, reaching about $775,000 in 2023, and received $13.0 million in milestone payments from Heska Corporation in December 2023. However, net cash used in operating activities was $18.1 million for the year. VolitionRx will host a conference call on March 26, 2024, to discuss these financial highlights and other updates.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 8:11 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.